$308 Million is the total value of Kynam Capital Management, LP's 33 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 21.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XENE | Sell | XENON PHARMACEUTICALS INC | $14,774,000 | -29.4% | 483,270 | -27.9% | 4.79% | -57.2% |
| LQDA | Sell | LIQUIDIA CORPORATION | $8,326,000 | +25.1% | 1,159,674 | -15.2% | 2.70% | -24.1% |
| BIIB | Sell | BIOGEN INC | $8,053,000 | -16.1% | 38,236 | -4.4% | 2.61% | -49.1% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $5,431,000 | -18.0% | 573,516 | -0.0% | 1.76% | -50.3% |
| FATE | Sell | FATE THERAPEUTICS INC | $3,541,000 | -36.7% | 91,337 | -4.4% | 1.15% | -61.6% |
| MRUS | Sell | MERUS N V | $3,087,000 | -20.5% | 116,764 | -4.4% | 1.00% | -51.8% |
| MCRB | Sell | SERES THERAPEUTICS INC | $2,075,000 | -18.3% | 291,443 | -4.4% | 0.67% | -50.4% |
| PBYI | Sell | PUMA BIOTECHNOLOGY INC | $1,882,000 | -9.4% | 653,445 | -4.4% | 0.61% | -45.1% |
| RDUS | Sell | RADIUS HEALTH INC | $1,638,000 | +22.0% | 185,514 | -4.4% | 0.53% | -26.0% |
| AFMD | Sell | AFFIMED N V | $1,521,000 | -24.3% | 347,965 | -4.4% | 0.49% | -54.1% |
| CABA | Sell | CABALETTA BIO INC | $1,251,000 | -48.8% | 616,125 | -4.4% | 0.41% | -68.9% |
| KRYS | Sell | KRYSTAL BIOTECH INC | $1,224,000 | -49.7% | 18,393 | -47.2% | 0.40% | -69.5% |
| OLMA | Sell | OLEMA PHARMACEUTICALS INC | $1,196,000 | -56.5% | 280,827 | -4.4% | 0.39% | -73.6% |
| NLTX | Sell | NEOLEUKIN THERAPEUTICS INC | $264,000 | -62.8% | 140,508 | -4.4% | 0.09% | -77.3% |
| CBIO | Sell | CATALYST BIOSCIENCES INC | $70,000 | -30.7% | 106,089 | -4.4% | 0.02% | -57.4% |
| ALLK | Exit | ALLAKOS INCcall | $0 | – | -74,500 | -100.0% | -0.00% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS INcall | $0 | – | -100,000 | -100.0% | -0.01% | – |
| COGT | Exit | COGENT BIOSCIENCES INC | $0 | – | -150,000 | -100.0% | -0.69% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -205,800 | -100.0% | -1.79% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 12.3% |
| CELLDEX THERAPEUTICS INC NEW | 8 | Q3 2023 | 14.4% |
| VAXCYTE INC | 8 | Q3 2023 | 10.9% |
| VERA THERAPEUTICS INC | 8 | Q3 2023 | 6.9% |
| TRAVERE THERAPEUTICS INC | 8 | Q3 2023 | 7.6% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 4.6% |
| BURNING ROCK BIOTECH LTD | 8 | Q3 2023 | 3.4% |
| AMARIN CORP PLC | 8 | Q3 2023 | 4.0% |
| LIQUIDIA CORPORATION | 8 | Q3 2023 | 3.6% |
| WAVE LIFE SCIENCES LTD | 8 | Q3 2023 | 3.7% |
View Kynam Capital Management, LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-03-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-01-10 |
View Kynam Capital Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.